Normal “heart” in Parkinson’s disease: Is this a distinct clinical phenotype?
Objective: The aim of this study was to investigate whether non-motor manifestations of Parkinson’s disease (PD) differ between patients with normal and abnormal myocardial metaiodobenzylguanidine (MIBG)…DaTscan in clinical evaluation of Multiple System Atrophy
Objective: To explore accuracy of DaTscanTM Ioflupane I123 Injection (DaTscan) in a multiple system atrophy (MSA) cohort Background: There are isolated cases of normal DaTscan in neuropathologically confirmed MSA-cerebellar subtype (MSA-C)…Neuroimaging studies in familial forms of Parkinson’s disease: A systematic review
Objective: We aim to systematically review the current status of MRI, PET and SPECT imaging in asymptomatic (aPD) and symptomatic (sPD) genetic carriers of PD.…Progression to Parkinson’s disease in carriers of LRRK2 G2019S mutation: a 4-year prospective study with serial dopamine transporter imaging
Objective: To assess whether any of the biomarkers studied (UPDRS-III, SN echogenicity, UPSIT and DaT-SPECT) in a baseline evaluation of a cohort of LRRK2 G2019S asymptomatic…Clinical Criteria for Subtyping Parkinson’s Disease: Differences in imaging and CSF biomarkers and longitudinal progression
Objective: To introduce a new practical classification method to assign individuals with Parkinson’s disease (PD) into distinct subtypes using baseline dataset, then to compare neuroimaging,…Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype
Objective: To investigate whether Parkinson's disease (PD) motor subtypes differ in their levels of uric acid (UA), and if these differences correlate with the degree…Striatal postsynaptic dysfunction in X-linked dystonia-parkinsonism is associated with disease progression
Objective: To assess pre- and postsynaptic dopaminergic function in X-linked dystonia-parkinsonism (XDP). Background: X-linked dystonia-parkinsonism (XDP) is a neurodegenerative adult-onset movement disorder associated with striatal…Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials
Objective: To evaluate subregion-dependent striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants in the Parkinson Progression Marker Initiative (PPMI)…Factors affecting the cardiac sympathetic denervation in autopsy confirmed dementia with Lewy bodies
Objective: To examine the relation among degeneration of the cardiac sympathetic nerve (CSN), clinical features and neuropathological findings in dementia with Lewy bodies (DLB). Background:…Evidence of striatal dopaminergic dysfunction Sydenham’s chorea in remission with (99m)Tc-TRODAT-1 SPECT
Objective: To report the findings of reduced striatal dopamine transporter (DAT) density in patients with Sydenham's chorea (SC) in remission assessed by single-photon emission computed…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.